Dupixent and Cutaneous TCell Lymphoma (CTCL)
Dupixent is commonly prescribed to treat eczema and other inflammatory conditions. While many patients have found relief from symptoms, growing medical research and FDA safety monitoring have raised serious concerns about a possible connection between Dupixent and CTCL.
We are currently reviewing cases where patients were treated with Dupixent and later diagnosed with CTCL.
Recent studies have found that people using Dupixent for eczema may have a significantly higher risk of being diagnosed with CTCL compared to patients who did not use the drug. Medical experts believe this may happen because Dupixent alters immune system signaling. While this helps calm inflammation and improve eczema symptoms, it may also:
- Hide early warning signs of CTCL
- Delay proper diagnosis
- Allow undetected lymphoma to progress unnoticed
What Is Cutaneous TCell Lymphoma (CTCL)?
CTCL is a rare form of nonHodgkin lymphoma that starts in Tcells, which are part of the immune system. Instead of fighting infection, these abnormal cells attack the skin.
CTCL often appears as:
- Persistent rashes
- Scaly or itchy patches
- Skin discoloration that does not improve
The two most common types include:
Mycosis Fungoides
- The most common form of CTCL
- Often begins as red, scaly patches that resemble eczema or psoriasis
- Can worsen over time and spread to lymph nodes or internal organs
Sézary Syndrome
- A more aggressive form
- Causes widespread redness, severe itching, swollen lymph nodes, and cancer cells in the blood
Dupixent and CTCL: What Researchers Are Seeing
In multiple reported cases, patients were prescribed Dupixent for eczema and later discovered to have CTCL. In some situations, symptoms worsened or failed to improve after starting the drug, leading doctors to perform biopsies that revealed lymphoma.
While researchers have not confirmed Dupixent as a direct cause, studies and FDA adverseevent data suggest the drug may:
- Unmask previously undiagnosed CTCL
- Delay diagnosis by suppressing visible symptoms
- Be associated with faster disease progression in some patients
Because of these concerns, doctors are urging greater caution and closer monitoring.
Symptoms to Watch for While Using Dupixent
If you are currently using Dupixent, pay close attention to changes in your skin and overall health.
Warning signs may include:
- Rashes or patches that do not heal
- Skin symptoms that worsen instead of improve
- Severe or spreading redness
- Swollen lymph nodes
- Ongoing fatigue or weakness
- Skin that no longer responds to treatment
If you notice any of these symptoms, contact your healthcare provider right away. A skin biopsy or blood test may be needed to rule out CTCL.
FDA Monitoring Dupixent and CTCL Reports
The U.S. Food and Drug Administration (FDA) is actively reviewing reports of CTCL in patients treated with Dupixent. The agency has acknowledged concerns that the drug may:
- Hide early signs of lymphoma
- Delay accurate diagnosis
- Be linked to serious immunerelated risks
As of now, the FDA has not issued a formal boxed warning, but it is evaluating whether updates to Dupixent’s safety labeling are needed.
The FDA encourages healthcare providers to closely monitor patients who are using Dupixent—especially if skin symptoms are unusual, worsening, or not responding to treatment. Patients are also urged to report new or persistent skin changes and seek further testing when appropriate.
